InnoCare Pharma Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Beijing, Beijing and currently employs 1,146 full-time employees. The company went IPO on 2020-03-23. InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The firm focuses on areas with large unmet clinical needs, such as oncology and autoimmune diseases. The firm's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The firm is also developing products for the treatment of autoimmune diseases caused by abnormal B cell or T cell function. The firm mainly conducts its businesses in domestic and overseas markets.
Follow-Up Questions
InnoCare Pharma Ltd のCEOは誰ですか？
Dr. Jisong Cui は InnoCare Pharma Ltd の Executive Chairman of the Board で、2015 から在籍しています。
INCPF の株価パフォーマンスは？
INCPF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
InnoCare Pharma Ltd の主な事業テーマや業界は？
InnoCare Pharma Ltd は Biotechnology 業界、セクターは Health Care に属しています。
